(XHS) SPDR S&P Health Care - Ratings and Ratios
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US78464A5737
XHS: Health, Care, Medical, Hospitals, Services
The SPDR S&P Health Care Services ETF (XHS) is designed to mirror the performance of the S&P Health Care Services Select Industry Index by employing a sampling strategy, investing at least 80% of its assets in the securities that comprise the index. This index is a subset of the S&P Total Market Index (S&P TMI), focusing specifically on the health care services segment.
The health care services sector is a critical component of the overall healthcare industry, encompassing companies that provide healthcare services, including hospitals, nursing homes, and healthcare facilities. The ETF provides investors with a diversified portfolio of companies within this segment, allowing for broad exposure to the sectors performance.
Analyzing the ETFs recent performance, we observe a bullish trend indicated by its current price being above its 20-day, 50-day, and 200-day Simple Moving Averages (SMA20, SMA50, SMA200). The Average True Range (ATR) stands at 2.08, suggesting moderate volatility. Given the current price is near its 52-week high, and considering the overall upward trend, theres potential for continued growth if the sector maintains its momentum.
Combining technical and fundamental insights, we can infer that the ETFs relatively small Assets Under Management (AUM) of $90.92M might impact its liquidity and trading costs. However, for investors looking to gain exposure to the health care services segment, XHS offers a targeted investment opportunity. Forecast suggests that if the health care services sector continues to grow, driven by demographic trends and healthcare demand, XHS could potentially see its price move towards the upper end of its 52-week range or beyond, assuming the overall market conditions remain favorable.
To make an informed investment decision, its crucial to monitor the ETFs tracking efficiency, fees, and how it responds to changes in the healthcare landscape, including regulatory changes and sector-specific trends. A thorough analysis of these factors, alongside ongoing technical and fundamental analysis, will be essential in determining the future performance of XHS.
Additional Sources for XHS ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
XHS ETF Overview
Market Cap in USD | 91m |
Category | Health |
TER | 0.35% |
IPO / Inception | 2011-09-28 |
XHS ETF Ratings
Growth Rating | 22.6 |
Fundamental | - |
Dividend Rating | 38.6 |
Rel. Strength | -4.39 |
Analysts | - |
Fair Price Momentum | 87.73 USD |
Fair Price DCF | - |
XHS Dividends
Dividend Yield 12m | 0.33% |
Yield on Cost 5y | 0.49% |
Annual Growth 5y | 8.64% |
Payout Consistency | 65.2% |
Payout Ratio | % |
XHS Growth Ratios
Growth Correlation 3m | 13.5% |
Growth Correlation 12m | 41.3% |
Growth Correlation 5y | -0.6% |
CAGR 5y | 7.82% |
CAGR/Max DD 5y | 0.24 |
Sharpe Ratio 12m | 0.21 |
Alpha | -2.73 |
Beta | 0.545 |
Volatility | 19.71% |
Current Volume | 31.2k |
Average Volume 20d | 6.6k |
As of June 17, 2025, the stock is trading at USD 96.67 with a total of 31,152 shares traded.
Over the past week, the price has changed by -1.53%, over one month by -2.02%, over three months by -0.27% and over the past year by +5.66%.
Neither. Based on ValueRay´s Analyses, SPDR S&P Health Care is currently (June 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 22.60 and therefor a technical neutral rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of XHS is around 87.73 USD . This means that XHS is currently overvalued and has a potential downside of -9.25%.
SPDR S&P Health Care has no consensus analysts rating.
According to our own proprietary Forecast Model, XHS SPDR S&P Health Care will be worth about 97.4 in June 2026. The stock is currently trading at 96.67. This means that the stock has a potential upside of +0.8%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 97.4 | 0.8% |